Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine
clinical trial
Press Enter · cited answer in seconds
0 sources
Summary
Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine is a clinical trial[1].
Key Facts
- Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine is in the country of United States[2].
- Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine's instance of is recorded as clinical trial[3].
- Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine's start time is recorded as +2016-11-29T00:00:00Z[4].
- Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine's end time is recorded as +2022-11-29T00:00:00Z[5].
- Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine's sponsor is recorded as University of Arizona[6].
- Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine's main subject is recorded as lymphoma[7].
- Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine's main subject is recorded as leukemia[8].
- Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine's main subject is recorded as Burkitt lymphoma[9].
- Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine's number of participants is recorded as {'unit': '1', 'amount': '+32'}[10].
- Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine's title is recorded as A Phase I/II Study of Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide and/or Bendamustine[11].
- Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+8'}[12].
- Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine's ClinicalTrials.gov ID is recorded as NCT02996773[13].
- Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+65'}[14].
- Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine's research intervention is recorded as (RS)-cyclophosphamide[15].
- Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine's research intervention is recorded as bendamustine hydrochloride[16].
- Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine's clinical trial phase is recorded as phase I clinical trial[17].
- Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine's clinical trial phase is recorded as phase II clinical trial[18].
- Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine's research site is recorded as University of Arizona[19].
- Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine's study type is recorded as interventional study[20].